MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

39.89 3.99

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

38.36

Massimo

40.31

Metriche Chiave

By Trading Economics

Entrata

7.3M

-123M

Vendite

3.7M

3.9M

EPS

-1.29

Margine di Profitto

-3,161.261

Dipendenti

594

EBITDA

20M

-122M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+116.99% upside

Dividendi

By Dow Jones

Utili prossimi

7 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-542M

3.9B

Apertura precedente

35.9

Chiusura precedente

39.89

Notizie sul Sentiment di mercato

By Acuity

50%

50%

168 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

8 apr 2026, 20:44 UTC

Utili

Costco Reports 11% Growth in March Sales

8 apr 2026, 23:51 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 apr 2026, 23:51 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8 apr 2026, 23:36 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Gold Edges Lower on Likely Technical Correction -- Market Talk

8 apr 2026, 22:56 UTC

Discorsi di Mercato

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8 apr 2026, 22:45 UTC

Discorsi di Mercato

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8 apr 2026, 22:17 UTC

Discorsi di Mercato

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8 apr 2026, 21:52 UTC

Principali Notizie su Eventi

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8 apr 2026, 21:24 UTC

Utili

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8 apr 2026, 21:01 UTC

Principali Notizie su Eventi

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8 apr 2026, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

8 apr 2026, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8 apr 2026, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8 apr 2026, 20:43 UTC

Acquisizioni, Fusioni, Takeovers

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8 apr 2026, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8 apr 2026, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8 apr 2026, 20:42 UTC

Acquisizioni, Fusioni, Takeovers

Oracle Responds to TRC Cap Mini-Tender Offer

8 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

8 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8 apr 2026, 19:44 UTC

Utili

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8 apr 2026, 19:16 UTC

Discorsi di Mercato

Hogs Follow Cutout Prices Lower -- Market Talk

8 apr 2026, 19:02 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

8 apr 2026, 19:02 UTC

Discorsi di Mercato

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8 apr 2026, 18:58 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8 apr 2026, 18:51 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

8 apr 2026, 18:51 UTC

Discorsi di Mercato

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8 apr 2026, 18:14 UTC

Principali Notizie su Eventi

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8 apr 2026, 18:05 UTC

Principali Notizie su Eventi

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

116.99% in crescita

Previsioni per 12 mesi

Media 86.71 USD  116.99%

Alto 97 USD

Basso 67 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

8

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

168 / 349 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat